Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.19 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:00 PM 10/30/14 All times are local (Market data is delayed by at least 15 minutes).

aeolus pharmaceuticals inc (IC9A) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

aeolus pharmaceuticals inc (IC9A) Related Businessweek News

No Related Businessweek News Found

aeolus pharmaceuticals inc (IC9A) Details

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops of a platform of novel compounds in biodefense, oncology, and pulmonary disorders. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound, AEOL 10150, which has completed 2 Phase I clinical trials is developed against the pulmonary sub-syndrome of acute radiation syndrome, as well as for the hematopoetic sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants, such as chlorine gas, sulfur mustard gas, phosgene gas, and nerve agents. The company is also developing AEOL 11207, AEOL 1114B, and AEOL 11203 for the treatment of epilepsy and Parkinson’s disease. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

4 Employees
Last Reported Date: 02/13/15
Founded in 1994

aeolus pharmaceuticals inc (IC9A) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $433.9K
Chairman of The Board, Chief Financial Office...
Total Annual Compensation: $352.6K
Compensation as of Fiscal Year 2014.

aeolus pharmaceuticals inc (IC9A) Key Developments

Aeolus Pharmaceuticals Inc. Receives Orphan Drug Designation from US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis

Aeolus Pharmaceuticals Inc. announced that it has received notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration granting Orphan Drug Designation for AEOL 10150 'for treatment of idiopathic pulmonary fibrosis'. Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits. The company is also developing AEOL 10150 as a treatment for cancer patients receiving radiation therapy and for the pulmonary and delayed effects of acute radiation exposure under a five-year contract with the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services.

Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended December 31, 2014

Aeolus Pharmaceuticals Inc. announced unaudited consolidated financial results for the first quarter ended December 31, 2014. For the quarter, the company reported a net loss of approximately $698,000 or $0.01 per share compared to $695,000 or $0.01 per share, for the three months ended December 31, 2013. Revenue was approximately $925,000 versus revenue of $793,000 for the three months ended December 31, 2013. Loss from operations was $698,000 against $695,000 a year ago. Net cash used in operating activities was $1,070,000 against $335,000 a year ago.

Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2014

Aeolus Pharmaceuticals Inc. announced consolidated earnings results for the fourth quarter and full year ended September 30, 2014. For the fourth quarter of fiscal year 2014, total revenues were $2,417,000 as compared to $883,000 in the fourth quarter of fiscal year 2013. Net loss for the fourth quarter in fiscal year of 2014 was $524,000 or ($0.0/share) as compared to $668,000 or ($0.0/share) in the fourth quarter of fiscal year 2013. For the year, the company reported contract revenue of $9,631,000 compared to $3,928,000 a year ago. Loss from operations was $80,000 compared to $2,698,000 a year ago. Net loss was $80,000 or $0.00 per basic and diluted share compared to $3,208,000 or $0.03 per basic and diluted share a year ago. Net loss attributable to common stockholders was $80,000 compared to $3,208,000 a year ago. Net cash provided by operating activities was $323,000 compared to net cash used in operating activities of $2,970,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IC9A:GR €0.19 EUR 0.00

IC9A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IC9A.
View Industry Companies

Industry Analysis


Industry Average

Valuation IC9A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 44.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEOLUS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at